Proceeds slated for clinical development and related manufacturing
By Susanna Moon
Chicago, Feb. 12 – Atara Biotherapeutics, Inc. said it priced an upsized $65.49 million public offering of common shares with an over-allotment option for another 545,749 shares. The deal was announced Jan. 28.
The company sold 3,638,333 shares at $18.00 per share, which is a 5.96% discount to the company’s closing price on Wednesday.
The company had planned to sell 3 million shares with a greenshoe for another 450,000 shares. The company had registered up to $86.25 million of stock.
Goldman Sachs & Co. and Citigroup Global Markets Inc. are the bookrunners.
Proceeds will be used for clinical development and related manufacturing, clinical trials, clinical studies, to expand and advance the company’s preclinical pipeline and for working capital and other general corporate purposes.
The biopharmaceutical company is based in Brisbane, Calif.
| Issuer: | Atara Biotherapeutics, Inc.
|
| Issue: | Common stock
|
| Amount: | $65,489,994
|
| Greenshoe: | For 545,749 shares
|
| Shares: | 3,638,333
|
| Price: | $18.00
|
| Warrants: | No
|
| Bookrunners: | Goldman Sachs & Co., Citigroup Global Markets Inc.
|
| Co-manager: | Jefferies LLC
|
| Announcement date: | Jan. 28
|
| Pricing date: | Feb. 11
|
| Settlement date: | Feb. 18
|
| Stock ticker: | Nasdaq: ATRA
|
| Stock price: | $19.14 on Feb. 11
|
| Market capitalization: | $351.08 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
